Physician profile
Skyler T Sharp
NPI 1538619473
$1,072.01
in general payments reported to CMS, 2019-2025
12 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2023: $61.19 · 2024: $277 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $345.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $172.29 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $167.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $91.91 | 2021-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $72.37 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $55.58 | 2021-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $40.42 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $35.17 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $30.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.05 | 2021 | |
| Boston Scientific Corporation | $20.04 | 2024 | Watchman Access System |
| Glaxosmithkline, LLC. | $17.05 | 2024 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skyler Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.